In vitro and in vivo enhancement of chemoradiation using the oral parp inhibitor ABT-888 in colorectal cancer cells

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 3, 2013, Pages 469-476

  Shelton, Joseph W ^a,b   Waxweiler, Timothy V ^a   Landry, Jerome ^a   Gao, Huiying ^a   Xu, Yanbo ^a   Wang, Lanfang ^a   El Rayes, Bassel ^a   Shu, Hui Kuo G ^a  

^a EMORY UNIVERSITY   (United States)

^b NE ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIOTHERAPY; CHEMOTHERAPY; POLYMERS; RADIOTHERAPY; REPAIR; TUMORS;

COLORECTAL CANCER CELL; COLORECTAL CARCINOMA; DOUBLE STRAND BREAKS; LOCALLY ADVANCED RECTAL CANCERS; METHODS AND MATERIALS; NEOADJUVANT CHEMORADIATION; PATHOLOGIC COMPLETE RESPONSE (PCR); SINGLE-STRAND BREAKS;

DISEASES;

FLUOROURACIL; IRINOTECAN; OXALIPLATIN; VELIPARIB; 2 ((R) 2 METHYLPYRROLIDIN 2 YL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CAMPTOTHECIN; DRUG DERIVATIVE; H2AFX PROTEIN, HUMAN; HISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLATINUM COMPLEX; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CELL STRAIN HCT116; CELL STRAIN HT29; CHEMORADIOTHERAPY; CLONOGENIC ASSAY; COLORECTAL CARCINOMA; COMET ASSAY; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LINEAR ACCELERATOR; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; XENOGRAFT; ANIMAL; COLORECTAL TUMOR; DNA DAMAGE; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; GENETICS; HUMAN; METHODOLOGY; NUDE MOUSE; PATHOLOGY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CAMPTOTHECIN; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; COMET ASSAY; DNA DAMAGE; FEMALE; FLUOROURACIL; HCT116 CELLS; HISTONES; HT29 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84880590413     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.02.015     Document Type: Article

References (16)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731-1740.
3. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997;94:7303-7307.
4. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
5. Shiobara M, Miyazaki M, Ito H, et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001; 16:338-344.
6. Tentori L, Leonetti C, Scarsella M, et al. Inhibition of poly(ADPribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 2006;20:1709-1711.
7. Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-3042.
8. Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNAdamaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-2737.
9. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-681.
10. Olive PL, Banáth JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 2006;1:23-29.
11. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835-844.
12. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638-1644.
13. Mohiuddin M. Randomized phase II study of neoadjuvant combinedmodality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006;24:650-655.
14. Fietkau R, Rodel C, Hohenberger W, et al. Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys 2007;67:1008-1019.
15. Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracilmediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 1994;29:519-523.
16. Wyatt MD, Wilson DM III. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 2009;66:788-799.